NASDAQ-NMS:SNPX

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Retrieved on: 
Wednesday, April 24, 2024
CUSIP, Therapy

NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.

Key Points: 
  • NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.
  • On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of $1.00 or more for 30 consecutive business days.
  • In order to regain compliance with the Listing Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
  • The Company conducted a 1-for-25 reverse split of its common stock on April 4, 2024, with the goal of increasing the trading price of the common stock.

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Retrieved on: 
Tuesday, April 9, 2024
Psilocybin, Alzheimer's disease, Partnership, Research, Parkinson's disease, Inflammatory bowel disease, Therapy, Intellectual property, Bryostatin, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul").
  • Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics.
  • Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").
  • Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors.

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Retrieved on: 
Wednesday, April 3, 2024
Transfer, Therapy, Common, Book, CUSIP, Sale, Exercise, Security (finance)

NEW YORK, April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. The reverse stock split will become effective at 5:00 p.m. Eastern Standard Time on Thursday, April 4, 2024. SNPX common stock will continue to be traded on The Nasdaq Capital Market under the symbol SNPX and will begin trading on a split-adjusted basis when the market opens on Friday, April 5, 2024. The new CUSIP number for SNPX common stock following the reverse stock split will be 87167T 300. The reverse split is intended to increase the per-share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Key Points: 
  • The new CUSIP number for SNPX common stock following the reverse stock split will be 87167T 300.
  • Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.
  • The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.
  • Stockholders who would otherwise hold a fractional share of the Company's common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the reverse stock split, April 4, 2024.

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

Retrieved on: 
Tuesday, December 19, 2023
Patient, School, Neurology, Alzheimer's disease, Drug discovery, Treatment, International Association, USC, Research, PKC, Biomedical sciences, BDNF, University, Dementia, Bangladesh Technical Education Board, NIH, Memory, Therapy, Pharmaceutical industry

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative Disorders."

Key Points: 
  • The award was presented by Giulio Maria Pasinetti, M.D., Ph.D., Saunders Family Chair and Professor of Neurology at the Icahn School of Medicine at Mount Sinai, lead spokesperson for the event.
  • In the trial, secondary efficacy endpoints were met with statistically significant benefits, p
  • No significant cognitive decline was observed throughout the 10-month study, and persistent benefits continued at least 16 weeks beyond the final dosing.
  • Dr. Alkon discussed how, in pre-clinical studies, Bryostatin-1, MW 904, an activator of PKC epsilon – BDNF pathways, demonstrated synaptogenic, anti-apoptotic, anti-amyloid, and anti-tau tangle efficacies…."

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Retrieved on: 
Wednesday, December 6, 2023
Alzheimer's disease, Research, Cell biology, Treatment, International Association, Neurotransmission, Learning, Disease, Patient, Journal, Therapy, Biomedical sciences, University, Memory, Dementia, Pharmaceutical industry, Medical device, Medicine, Physiology, Pharmacy, NEW YORK

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders." The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences (IABS).

Key Points: 
  • The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences (IABS).
  • The forum's keynote address, entitled "Towards a Cell Biology of Alzheimer's Disease," will be delivered by Dr. Thomas Südhof, Nobel Laureate in Physiology or Medicine 2013.
  • Dr. Südhof is known for his groundbreaking research on the mechanisms underlying synaptic transmission, which plays a vital role in learning, memory, and various neurological processes.
  • A research article detailing the results was published earlier this year in the Journal of Alzheimer's Disease.

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Retrieved on: 
Thursday, November 2, 2023
Cannabis, Science, MIT, Therapy, Intellectual property, Cannabinoid, University of Freiburg Faculty of Biology, Research, Technology Development Foundation of Turkey, Sleep, Laboratory, Partnership, Leukemia, Nobel Prize, Epilepsy, Patient, Massachusetts Institute of Technology, Pharmaceutical industry, Biology, Technion – Israel Institute of Technology

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new partnership with Cannasoul Analytics Ltd. ("Cannasoul") in support of research and development of pharmaceutical therapeutics. Cannasoul is founded by the Technion Research & Development Foundation ("TRDF"), the commercialization arm of The Technion – Israel Institute of Technology ("The Technion"), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion.

Key Points: 
  • Cannasoul is founded by the Technion Research & Development Foundation ("TRDF"), the commercialization arm of The Technion – Israel Institute of Technology ("The Technion"), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion.
  • Professor Meiri and The Technion founded Cannasoul in 2018 for the development of cannabinoid-based and other therapeutics for various indications and vertical markets.
  • Cannasoul has developed technology in large disease markets including leukemia ($12.7B by 20281), epilepsy ($14.7B by 20332), and sleep disorders ($73.5B by 20323).
  • "Cannasoul is pleased to welcome Synaptogenix as a key partner in our development of groundbreaking therapeutics derived from natural compounds.

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Retrieved on: 
Wednesday, July 19, 2023
Learning, US Food Sovereignty Alliance, Cleveland Clinic, Therapy, Cognitive deficit, Drug discovery, Clinical trial, Deficit spending, Research, Brain, Multiple sclerosis, Remyelination, MS, MRI, Barrow Neurological Institute, Regeneration, Fragile X syndrome, MD, Immune system, Synapse, Protein kinase C, Principal, Magnetic resonance imaging, IND, Memory, Alzheimer's disease, Food, Safety, Disease, Pharmaceutical industry

NEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). Cleveland Clinic will manage the clinical trial's implementation, including an Investigational New Drug (IND) submission to the US Food and Drug Administration and patient enrollment.

Key Points: 
  • Cleveland Clinic will manage the clinical trial's implementation, including an Investigational New Drug (IND) submission to the US Food and Drug Administration and patient enrollment.
  • "Cognitive impairment is a major unmet need in the treatment of people living with MS and we look forward to exploring the potential impact of this investigational drug."
  • Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix, added, "We are moving forward with our clinical development plans for Bryostatin-1 in MS in collaboration with Cleveland Clinic.
  • The planned clinical trial will be held at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis, one of the largest and most comprehensive programs for MS care and research worldwide.

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Retrieved on: 
Thursday, July 13, 2023
IBRO, Therapy, DSMB, Bryostatin, NIH, MCI, National Institutes of Health, Dementia, Bangladesh Technical Education Board, Data monitoring committee, International Brain Research Organization, Congress, Acquisition, Patient, SIB, AD, World Congress, MMSE, Alzheimer's disease, Safety, Pharmaceutical industry, Neuroscience

NEW YORK, July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that an abstract featuring secondary endpoint data of its National Institutes of Health (NIH) sponsored Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization (IBRO) World Congress of Neuroscience to be held in September 2023 in Spain.

Key Points: 
  • All patients were randomized with respect to treatment groups, with safety checked by an independent Data Safety Monitoring Board (DSMB).
  • Data also showed statistical significance in exploratory secondary endpoints for this Severe Cohort (MMSE 10-14 stratum), and post hoc analysis was positive.
  • "We are pleased that the IBRO World Congress has recognized our findings on the cognitive benefits of Bryostatin-1 for advanced and severe AD patients.
  • As of March 31, 2023, Synaptogenix maintains a clean capital structure and strong cash position of $35.8 million.

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Retrieved on: 
Tuesday, March 7, 2023
Alzheimer's disease, National Institutes of Health, Therapy, Dupont Hospital, Acquisition, Cleveland Clinic, Clinical trial, Mini–Mental State Examination, SIB, Disease, Week, AD, MMSE, Safety, Pharmaceutical industry, Medical imaging

Dr. Alan Tuchman, Synaptogenix Chief Executive Officer, stated, "Senior management and our Board of Directors have concluded an exploratory review of our business operations.

Key Points: 
  • Dr. Alan Tuchman, Synaptogenix Chief Executive Officer, stated, "Senior management and our Board of Directors have concluded an exploratory review of our business operations.
  • In the meantime, we continue to evaluate the use of Bryostatin-1 with our previously announced strategic partners for additional indications, Cleveland Clinic and Nemours A.I.
  • As we evaluate these business opportunities, our primary focus is creating shareholder value, and we look forward to updating our investors on our new initiatives in the near term."
  • Data also showed statistical significance in exploratory secondary endpoints for the MMSE-2 10-14 stratum, and post hoc analysis was positive.

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Retrieved on: 
Wednesday, October 19, 2022
U.S. Securities and Exchange Commission, Orphan, Disease, Government, Neurodegeneration, Stroke, Multiple sclerosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Drug development, Alzheimer's disease, Security (finance), Fragile X syndrome, Food, Bryostatin, Neuron, Company, Safety, AD, Brain, Death, Pharmaceutical industry

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that President and Chief Scientific Officer Daniel L. Alkon, M.D. will deliver a presentation and host meetings with investors at the upcoming ThinkEquity Conference.

Key Points: 
  • Now is one of the most exciting times in our Company history as we await topline data from our Phase 2 trial."
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.